Amicus Therapeutics (FOLD) signed a license agreement to commercialize of Dimerix's DMX-200, a kidney disease therapy candidate for all indications, including Focal Segmental Glomerulosclerosis, or FSGS, the companies said Wednesday.
In exchange for the US rights, Dimerix will receive a $30 million upfront payment, up to $560 million in milestone payments, and tiered royalties on US sales, according to the statement.
DMX-200 is under a phase 3 study for the treatment of FSGS, with full enrollment for the study expected by the end of the year, the companies said.
Dimerix will continue to fund and execute the phase 3 study, while Amicus will be in charge of the regulatory process and commercialization in the US. Amicus will have the exclusive rights to develop DMX-200 in other future indications in the US.
Dimerix retains rights in other territories, according to the statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.